Eli Lilly

Semaglutide generics hit Mounjaro sales, market share after patent expiry

Generic semaglutide surge dents Mounjaro sales, reshaping India's fast-growing GLP-1 diabetes and obesity drug market

Eli Lilly's Mounjaro sales dip as semaglutide generics flood Indian market

Mounjaro sales in March dropped to ₹114 crore ($12.3 million) in March from ₹135 crore a month earlier, Pharmarack data show

Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly

Pharmaceutical companies are increasingly turning to AI to accelerate R&D, betting on new modelling tools and automated labs to unlock efficiency gains across their pipeline

Goyal meets Eli Lilly Prez; discusses steps to strengthen 'Make in India'

Union Commerce and Industry Minister Piyush Goyal held a meeting with Patrik Jonsson, Executive Vice President and President of Lilly International, discussing India's growth trajectory and the company's expanding presence in the country.Sharing details of the meeting on X, Goyal said on Friday that the discussions focused on Eli Lilly and Company's increasing operations and investments in India, and ways to further strengthen the 'Make in India for the world' initiative."Held a meeting with Patrik Jonsson, Executive VP and President, Lilly International, USA. We discussed the India growth story, Eli Lilly & Company's expanding operations and investments in India, and the steps to further strengthen Make in India for the world," the post read.Earlier in the day, Piyush Goyal held a virtual meeting with Harry Theoharis, Greece's Deputy Minister of Foreign Affairs. He highlighted that the discussions revolved around deepening cooperation between India and Greece."Held a virtual ...

Eli Lilly banks on tirzepatide's clinical edge as GLP-1 generics loom

Lilly positions tirzepatide as a clinically superior option as semaglutide patent expiry triggers a wave of generics, intensifying competition in India's diabetes and obesity market

Popular weight-loss drugs shouldn't carry suicide warnings, FDA says

Federal regulators have told drugmakers Novo Nordisk and Eli Lilly to remove label warnings about potential suicidal thoughts and behaviours from their blockbuster weight-loss medications. The US Food and Drug Administration on Tuesday said a comprehensive review found no increased risk related to suicide among users of the GLP-1 drugs for obesity, including Novo Nordisk's Wegovy and Saxenda and Eli Lilly's Zepbound. A preliminary review in January 2024 showed no link between the drugs and suicidal thought or actions, the FDA said. At that time, however, officials said they could not rule out that a small risk may exist. The new analysis puts those concerns to rest. Labeling for other drugs known as GLP-1 receptor agonists approved to treat diabetes carried no such warnings, the agency noted. Today's FDA action will ensure consistent messaging across the labelling for all FDA-approved GLP-1 RA medications, officials said.

Eli Lilly, Novo Nordisk compete for lead in India's obesity drug market

Novo's strategy emphasises price cuts and accelerated launches, while Lilly's products benefitted from hitting the market early

GLP-1 weight-loss drugs likely to see value growth slowing down

Entry of generics post March 2026, patient dropouts to affect sales values, say experts

Price cuts drove market gains in November for Novo Nordisk's Wegovy

Novo Nordisk cut Wegovy prices in mid-November, driving a 70% consumption jump and higher market share. Pharmarack data show Lilly's Mounjaro still dominates sales

Eli Lilly, Pfizer drugs added to China's first private insurance list

As China's aging population increases demand for therapies treating everything from cancer and diabetes to dementia, the inclusion of these drugs may ease the burden on state medical insurance

Lilly's Donanemab gets CDSCO approval for early Alzheimer's treatment

Eli Lilly has secured CDSCO marketing authorisation for donanemab, an amyloid-targeting therapy for adults with early symptomatic Alzheimer's

Lilly's investment reflects long-term commitment to India: Winselow Tucker

Eli Lilly invests $1B in India as Mounjaro succeeds, Hyderabad site to boost global supply and innovation

Novo Nordisk, Emcure Pharma to launch weight-loss drug under new brand

The deal will help expand the availability and marketing of this weight-loss medicine, especially in areas where Novo Nordisk's reach is limited

Mounjaro India's bestselling drug in October with ₹100 crore sales

Weight-loss drug rakes in ₹333 cr in cumulative sales since launch in March this year, leaving rival Wegovy behind

Lilly and Cipla to market tirzepatide in India under new brand Yurpeak

The Lilly-Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and obesity care across urban and semi-urban markets

Eli Lilly's Mounjaro logs ₹80 crore in September, India's No. 2 drug

Eli Lilly's weight-loss injection Mounjaro saw a 42% jump in September sales, touching Rs 80 crore as more patients shift to higher doses amid rising demand

Eli Lilly to pump $1 billion into India to boost contract manufacturing

The US pharma major to set up a manufacturing and supply hub in Hyderabad as part of a $1 billion investment aimed at boosting contract production in India

Eli Lilly to invest over $1 billion in India to boost manufacturing

Eli Lilly, which launched its obesity drug Mounjaro in India earlier this year, plans to invest $1 billion to strengthen manufacturing partnerships and set up a new Hyderabad facility

India to get Novo Nordisk's Ozempic soon as demand for obesity drugs surges

Novo Nordisk's Ozempic launch adds to its GLP-1 portfolio, offering patients new options while competing with Eli Lilly's Mounjaro in India

'Worst in Europe': Eli Lilly CEO slams UK drug prices, warns of fewer drugs

Eli Lilly CEO Dave Ricks slammed the UK's strict drug pricing rules, warning that the country risks losing new medicines and investment unless changes are made to its rebate scheme